Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Neuroendocrine Tumors 9Thyroid Neoplasms 3Thyroid Cancer, Papillary 3Carcinoma, Medullary 3Carcinoid Tumor 3Adrenocortical Carcinoma 3Adenocarcinoma, Follicular 3Pheochromocytoma 2Paraganglioma 2Carcinoma, Renal Cell 2Carcinoma, Neuroendocrine 2Adenoma, Islet Cell 2Wilms Tumor 1Thyroid cancer, medullary 1Thyroid cancer, follicular 1Thyroid Diseases 1Thyroid Carcinoma, Anaplastic 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma 1Paraganglioma, Extra-Adrenal 1Osteosarcoma 1Non functioning pancreatic endocrine tumor 1Neoplasm Metastasis 1Metastatic Digestive System Neuroendocrine Tumor G1 1High Grade Neuroendocrine Neoplasms 1Hepatoblastoma 1

Interventions

vandetanib 1sacubitril and valsartan sodium hydrate drug combination 1lenvatinib 1fluorodopa F 18 1cabozantinib 1Sorafenib 13-(3'-adamantan-1-yl-4'-methoxybiphenyl-4-yl)-2-propenoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid cancer, medullary × cabozantinib × Endocrine × Clear all
NCT03630120 2021-07-14

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
6 enrolled 9 charts
EndocrineHead & Neck

Thyroid cancer, medullary, Thyroid Cancer, Papillary, Thyroid Diseases, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡